Maribavir for Treatment of Cytomegalovirus Infections Resistant or Refractory to Ganciclovir or Foscarnet in Hematopoietic Stem Cell Transplant or Solid Organ Transplant Recipients: A Randomized, Dose-Ranging, Double-Blind, Phase 2 Study

被引：0

作者：

Papanicolaou, Genovefa A. ^{[1
]}

Silveira, Fernanda P. ^{[2
]}

Langston, Amelia A. ^{[3
]}

Pereira, Marcus R. ^{[4
]}

Avery, Robin K. ^{[5
]}

Wijatyk, Anna ^{[6
]}

Wu, Jingyang J. ^{[6
]}

Boeckh, Michael J. ^{[7
]}

Marty, Francisco M. ^{[8
]}

Villano, Stephen ^{[9
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[2] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA

[3] Winship Canc Inst, Atlanta, GA USA

[4] Columbia Univ, Med Ctr, New York, NY USA

[5] Johns Hopkins Univ, Baltimore, MD USA

[6] Shire, Lexington, MA USA

[7] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA

[8] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA

[9] Shire, Wayne, PA USA

来源：

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | 2017年 / 23卷 / 03期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：S51 / S52

页数：2

共 50 条

[21] A Phase 3 Active-Controlled Study of Maribavir (MBV) for the Treatment (Tx) of Transplant Recipients with Refractory/Resistant (RR) Cytomegalovirus (CMV): Study Design [J].

Sandberg, Aimee ;

Alain, Sophie ;

Avery, Robin ;

Blumberg, Emily ;

Kamar, Nassim ;

Kotton, Camille ;

Silveira, Femanda ;

Wu, Jingyang .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2020, 26 (03) :S370-S371

[22] Cytomegalovirus (CMV) prophylaxis with alternate day ganciclovir/foscarnet in at risk pediatric allogeneic stem cell transplant (AlloSCT) recipients is 100% effective in preventing CMV infections and reducing ganciclovir hematopoietic toxicity. [J].

Shereck, EB ;

Bessmertny, O ;

Cooney, EM ;

Harrison, L ;

van de Ven, C ;

Wischhover, C ;

Wolownik, K ;

Del Toro, G ;

Bradley, MB ;

George, D ;

Garvin, J ;

Cairo, MS .

BLOOD, 2002, 100 (11) :627A-627A

[23] Randomized Phase 3 Open-label Study of Maribavir vs Investigator-assigned Therapy for Refractory/resistant Cytomegalovirus Infection in Transplant Recipients: Subgroup Analyses of Efficacy by Organ [J].

Avery, R. K. ;

Blumberg, E. A. ;

Florescu, D. ;

Kamar, N. ;

Kumar, D. ;

Wu, J. ;

Sundberg, A. .

AMERICAN JOURNAL OF TRANSPLANTATION, 2021, 21 :441-441

[24] Cytomegalovirus related hospitalization costs among hematopoietic stem cell and solid organ transplant recipients treated with maribavir versus investigator-assigned therapy: A US-based study [J].

Schultz, Bob G. ;

Bullano, Michael ;

Paratane, Deepika ;

Rajagopalan, Krithika .

TRANSPLANT INFECTIOUS DISEASE, 2024, 26 (02)

[25] A Double-Blind, Randomized Trial of High-Dose vs Standard-Dose Influenza Vaccine in Adult Solid-Organ Transplant Recipients [J].

Natori, Yoichiro ;

Shiotsuka, Mika ;

Slomovic, Jaclyn ;

Hoschler, Katie ;

Ferreira, Victor ;

Ashton, Peter ;

Rotstein, Coleman ;

Lilly, Les ;

Schiff, Jeffrey ;

Singer, Lianne ;

Humar, Atul ;

Kumar, Deepali .

CLINICAL INFECTIOUS DISEASES, 2018, 66 (11) :1698-1704

[26] Injectable DaxibotulinumtoxinA for the Treatment of Glabellar Lines: A Phase 2, Randomized, Dose-Ranging, Double-Blind, Multicenter Comparison With OnabotulinumtoxinA and Placebo [J].

Carruthers, Jean ;

Solish, Nowell ;

Humphrey, Shannon ;

Rosen, Nathan ;

Muhn, Channy ;

Bertucci, Vince ;

Swift, Arthur ;

Metelitsa, Andrei ;

Rubio, Roman G. ;

Waugh, Jacob ;

Quiring, John ;

Shears, Gill ;

Carruthers, Alastair .

DERMATOLOGIC SURGERY, 2017, 43 (11) :1321-1331

[27] Treatment for First Cytomegalovirus Infection Post-Hematopoietic Cell Transplant in the AURORA Trial: A Multicenter, Double-Blind, Randomized, Phase 3 Trial Comparing Maribavir With Valganciclovir (vol 78, pg 562, 2024) [J].

Papanicolao, Genovef A. ;

Avery, Robin K. ;

Cordonnie, Catherine ;

Duarte, Rafael F. ;

Haider, Shariq ;

Maertens, Johan ;

Peggs, Karl S. ;

Solano, Carlos ;

Young, Jo-Anne H. ;

Fournier, Martha ;

Murray, Rose Ann ;

Wu, Jingyang ;

Winston, Drew J. .

CLINICAL INFECTIOUS DISEASES, 2024, 79 (03) :803-803

[28] Lessons Learned From a Randomized Study of Oral Valganciclovir Versus Parenteral Ganciclovir Treatment of Cytomegalovirus Disease in Solid Organ Transplant Recipients: The VICTOR Trial [J].

Asberg, Anders ;

Humar, Atul ;

Rollag, Halvor ;

Jardine, Alan G. ;

Kumar, Deepali ;

Aukrust, Pal ;

Ueland, Thor ;

Bignamini, Angelo A. ;

Hartmann, Anders .

CLINICAL INFECTIOUS DISEASES, 2016, 62 (09) :1154-1160

[29] A Randomized Double-blind Placebo-controlled Phase 2 Dose-ranging Study of OnabotulinumtoxinA in Men with Benign Prostatic Hyperplasia [J].

Marberger, Michael ;

Chartier-Kastler, Emmanuel ;

Egerdie, Blair ;

Lee, Kyu-Sung ;

Grosse, Joachim ;

Bugarin, Denise ;

Zhou, Jihao ;

Patel, Anand ;

Haag-Molkenteller, Cornelia .

EUROPEAN UROLOGY, 2013, 63 (03) :496-503

[30] A phase 2, double-blind, multicenter, randomized, placebo-controlled, dose-ranging study of the efficacy and safety of Astodrimer Gel for the treatment of bacterial vaginosis [J].

Waldbaum, Arthur S. ;

Schwebke, Jane R. ;

Paull, Jeremy R. A. ;

Price, Clare F. ;

Edmondson, Stephanie R. ;

Castellarnau, Alex ;

McCloud, Philip ;

Kinghorn, George R. .

PLOS ONE, 2020, 15 (05)

← 1 2 3 4 5 →